Doubling Down on BRCA -Mutated Cancer
Copyright policy )Doubling Down on BRCA -Mutated Cancer
Immunotherapy is changing the landscape of cancer treatment. Nonetheless, not all malignancies respond, possibly due to low mutational load. Recent work in a TP53-/-BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not. These findings suggest an approach to enhance the impact of immune checkpoint blockade in BRCA-mutated tumors.
- Mayo Clinic United States
- University of Mary United States
- University of Washington United States
Mice, Knockout, Mice, Lymphocytes, Tumor-Infiltrating, BRCA1 Protein, Animals, Humans, Breast Neoplasms, Female, Mammary Neoplasms, Animal, Immunotherapy, Tumor Suppressor Protein p53, DNA Damage
Mice, Knockout, Mice, Lymphocytes, Tumor-Infiltrating, BRCA1 Protein, Animals, Humans, Breast Neoplasms, Female, Mammary Neoplasms, Animal, Immunotherapy, Tumor Suppressor Protein p53, DNA Damage
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!